DGAP-News: Fresenius Medical Care completes sale of clinics as part of Liberty Dialysis acquisition

DGAP-News: Fresenius Medical Care AG&Co. KGaA / Key word(s):
Disposal
Fresenius Medical Care completes sale of clinics as part of Liberty
Dialysis acquisition

02.04.2012 / 16:02

———————————————————————

Investor News of April 2, 2012

Fresenius Medical Care completes sale of clinics as part of Liberty
Dialysis acquisition

Bad Homburg, Germany – Fresenius Medical Care AG&Co. KGaA (–the company–
or –Fresenius Medical Care–), the world–s largest provider of dialysis
products and services, announced today that Fresenius Medical Care North
America (FMCNA) completed the sale of 45 dialysis clinics to Dialysis
Newco, Inc. (–DSI Renal–). An additional 10 clinics are expected to be sold
to DSI Renal following receipt of state regulatory approvals.

The divestiture was required in connection with the Federal Trade
Commission–s clearance of FMCNA–s acquisition of Liberty Dialysis Holdings
Inc., the holding company of Liberty Dialysis and Renal Advantage, which
closed on February 28, 2012.

Fresenius Medical Care is the world–s largest integrated provider of
products and services for individuals undergoing dialysis because of
chronic kidney failure, a condition that affects more than 2.1 million
individuals worldwide. Through its network of 2,898 dialysis clinics in
North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius
Medical Care provides dialysis treatment to 233,156 patients around the
globe. Fresenius Medical Care is also the world–s leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products.

For more information about Fresenius Medical Care, visit the Company–s
website at www.fmc-ag.com.

Disclaimer
This release contains forward-looking statements that are subject to
various risks and uncertainties. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Fresenius Medical Care AG&Co. KGaA–s reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG&Co.
KGaA does not undertake any responsibility to update the forward-looking
statements in this release.

End of Corporate News

———————————————————————

02.04.2012 Dissemination of a Corporate News, transmitted by DGAP – a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP–s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

———————————————————————

Language: English
Company: Fresenius Medical Care AG&Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172- 609 2525
Fax: +49 (0) 6172- 609 2301
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.de
ISIN: DE0005785802, DE0005785836,
WKN: 578580, 578583
Indices: DAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart; Terminbörse EUREX; NYSE

End of News DGAP News-Service
———————————————————————
163614 02.04.2012

  fresenius-medical-care-completes-sale-of-clinics-as-part-of-liberty-dialysis-acquisition